References
- Guaita, M., & Högl, B. (2016, February 1). Current treatments of bruxism. Current Treatment Options in Neurology, 18 (2), 1–15. https://doi.org/10.1007/s11940-016-0396-3
- Hogan, D. B., Jetté, N., Fiest, K. M., Roberts, J. I., Pearson, D., Smith, E. E., Roach, P., Kirk, A., Pringsheim, T., & Maxwell, C. J. (2016, April 1). The prevalence and incidence of frontotemporal dementia: A systematic review. Canadian Journal of Neurological Sciences, 43 (S1), S96–S109. https://doi.org/10.1017/cjn.2016.25
- Jankovic, J., Tan, E. K., & Ondo, W. (2000). Bruxism in Huntington’s disease. Movement Disorders, 15(1), 171–173. https://doi.org/10.1002/1531-8257(200001)15:1<171::AID-MDS1031>3.0.CO;2-Y
- Kishi, Y. (2007). Paroxetine-induced bruxism effectively treated with tandospirone [8]. Journal of Neuropsychiatry and Clinical Neurosciences, 19 (1), 90–91. https://doi.org/10.1176/jnp.2007.19.1.90
- Kwak, Y. T., Han, I. W., Lee, P. H., Yoon, J. K., & Suk, S. H. (2009). Associated conditions and clinical significance of awake bruxism. Geriatrics & Gerontology International, 9 (4), 382–390. https://doi.org/10.1111/j.1447-0594.2009.00538.x
- Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan-Wright, E. M. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology, 172 (20), 4790–4805. https://doi.org/10.1111/bph.13250
- Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Crippa, A. S. J. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Current Drug Safety, 6 (4), 237–249. https://doi.org/10.2174/157488611798280924
- Mackie, K. (2005). Distribution of cannabinoid receptors in the central and peripheral nervous system. Cannabinoids, 2005;(168): 299–325. https://doi.org/10.1007/3-540-26573-2_10
- Martínez-Pinilla, E., Varani, K., Reyes-Resina, I., Angelats, E., Vincenzi, F., Ferreiro-Vera, C., Oyarzabal, J., Canela, E. I., Lanciego, J. L., Nadal, X., Navarro, G., Borea, P. A., & Franco, R. (2017). Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Frontiers in Pharmacology, 8 : 744. https://doi.org/10.3389/fphar.2017.00744
- Murley, A. G., & Rowe, J. B. (2018, May 1). Neurotransmitter deficits from fronto temporal lobar degeneration. Brain, 141 (5), 1263–1285. https://doi.org/10.1093/brain/awx327
- Nitecka-Buchta, A., Nowak-Wachol, A., Wachol, K., Walczyńska-Dragon, K., Olczyk, P., Batoryna, O., Kempa, W., & Baron, S. (2019). Myorelaxant effect of transdermal cannabidiol application in patients with TMD: A randomized, double-blind trial. Journal of Clinical Medicine, 8 (11), 1886. https://doi.org/10.3390/jcm8111886
- Peres, F. F., Lima, A. C., Hallak, J. E. C., Crippa, J. A., Silva, R. H., & Abílio, V. C. (2018, May 11). Cannabidiol as a promising strategy to treat and prevent movement disorders? Frontiers in Pharmacology, 9 : 482. https://doi.org/10.3389/fphar.2018.00482.
- Pertwee, R. G. (2008, January). The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9-tetrahydrocannabinol, cannabidiol and Δ 9-tetrahydrocannabivarin. British Journal of Pharmacology, 153 (2), 199–215. https://doi.org/10.1038/sj.bjp.0707442
- Raveendranathan, D., & Rao, S. G. (2015). Sertraline induced acute mandibular dystonia. Journal of Neurosciences in Rural Practice, 6 (4), 586–587. https://doi.org/10.4103/0976-3147.169804
- Sales, A. J., Crestani, C. C., Guimarães, F. S., & Joca, S. R. L. (2018). Antidepressant-like effect induced by cannabidiol is dependent on brain serotonin levels. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 86, 255–261. https://doi.org/10.1016/j.pnpbp.2018.06.002